Renovorx Inc Stock Price, News & Analysis

RenovoRx (NASDAQ: RNXT) has announced the presentation of new pre-clinical data at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting. The abstract focuses on pharmacodynamics comparing intra-arterial versus intravenous gemcitabine in Locally Advanced Pancreatic Cancer (LAPC).

The presentation will showcase additional human pharmacokinetic (PK) and pre-clinical data supporting RenovoRx's proprietary Trans-Arterial Micro-Perfusion (TAMP™) therapy platform. This technology, utilizing the FDA-cleared RenovoCath® device, is designed to deliver targeted therapeutic treatment near tumor sites while potentially reducing systemic toxicities.

The company's ongoing Phase III TIGeR-PaC clinical trial is evaluating their investigational drug-device combination product (IAG) for LAPC treatment. RenovoRx expects to complete both patient enrollment and the second interim analysis for TIGeR-PaC in mid-2025.

RenovoRx (NASDAQ: RNXT) announced new purchase orders for its RenovoCath drug-delivery device from several National Cancer Institute-designated centers, including repeat orders from initial customers from December. The company expects to generate initial revenues this quarter, with potential revenue growth through 2025.

The FDA-cleared RenovoCath device is priced between $7,000 to $9,000 per unit, with an expected 5 to 8 annual procedures per patient. Based on these metrics and their initial target customer base, RenovoRx estimates a potential $400 million peak annual U.S. market for RenovoCath as a standalone device.

RenovoRx recently presented promising pre-clinical data at the SIO 2025 Annual Conference in Las Vegas. The data, derived from a study using the company's patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, suggests improved drug delivery in tumors with poor blood supply. The study utilized the FDA-cleared RenovoCath device in a porcine model, demonstrating enhanced drug penetration via micro-CT imaging.

Key findings include the ability to isolate blood vessel sections through adjustable occlusion balloons, leading to targeted drug delivery. The study also indicated that pre-application of radiation might enhance drug penetration further. This technique could be particularly beneficial for difficult-to-treat cancers like pancreatic adenocarcinoma.

RenovoRx's CEO, Shaun Bagai, highlighted the potential commercialization of RenovoCath as a stand-alone device for various medical applications. The TAMP therapy platform was also discussed in a panel at SIO 2025, emphasizing its potential to revolutionize cancer treatment.

RenovoRx (RNXT) has successfully closed a $12.1 million underwritten public offering of common stock, selling 11,523,810 shares at $1.05 per share. The offering, led by new fundamental healthcare institutional investors, generated net proceeds of approximately $10.9 million after deducting underwriting costs and expenses.

The company plans to use the proceeds for working capital and general corporate purposes, including advancing its Phase III TIGeR-PaC study and developing commercial activities for its FDA-cleared RenovoCath delivery system. The company anticipates key milestones in 2025, including first RenovoCath sales revenue, completion of Phase III trial enrollment, and a second interim data readout.

Titan Partners Group, a division of American Capital Partners, served as the sole bookrunner for the offering, which closed on February 10, 2025.

RenovoRx (RNXT) has announced the pricing of an underwritten public offering of 11,523,810 shares of common stock at $1.05 per share, expecting to raise gross proceeds of approximately $12.1 million. The offering is scheduled to close on February 10, 2025, subject to customary closing conditions.

The company plans to use the net proceeds for working capital and general corporate purposes, including the progression of its Phase III TIGeR-PaC study and the development of commercial sales and marketing activities for RenovoCath, their FDA-cleared delivery platform. Titan Partners Group, a division of American Capital Partners, is serving as the sole bookrunner for this offering.

RenovoRx (Nasdaq: RNXT) has announced a proposed underwritten public offering of common stock and pre-funded warrants. The company plans to use the proceeds for working capital and general corporate purposes, including the progression of its Phase III TIGeR-PaC study and the development of commercial sales and marketing activities for RenovoCath, their FDA-cleared delivery platform.

Titan Partners Group, a division of American Capital Partners, is acting as the sole bookrunner for the offering. The offering is being made through a shelf registration statement previously filed with the SEC. The final size, terms, and completion of the offering are subject to market conditions.

RenovoRx (NASDAQ: RNXT) presented promising pharmacokinetic (PK) data from their Phase III TIGeR-PaC clinical trial at ASCO GI 2025. The study, presented by Dr. Paula Novelli from the University of Pittsburgh Medical Center, compared intra-arterial gemcitabine (IAG) delivery using RenovoRx's Trans-Arterial Micro-Perfusion (TAMP) therapy platform versus standard intravenous treatment in locally advanced pancreatic cancer (LAPC).

The sub-study results demonstrated that RenovoRx's IAG approach via TAMP reduced systemic levels of gemcitabine compared to standard care, potentially decreasing related side effects while increasing local drug potency. The TAMP platform, utilizing the FDA-cleared RenovoCath® delivery system, is designed to precisely deliver therapy across the arterial wall near tumor sites.

RenovoRx (RNXT) announced the acceptance of three abstracts for presentation at major industry conferences: ASCO GI 2025, SIO 2025, and SSO 2025. The abstracts focus on the company's Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, presenting additional human pharmacokinetic data and pre-clinical results.

The presentations will highlight RenovoRx's novel approach using their FDA-cleared RenovoCath® delivery platform, which is designed to deliver targeted oncology therapies directly to tumor sites while potentially reducing toxicity compared to systemic treatments. The company's ongoing Phase III TIGeR-PaC clinical trial is evaluating their first product candidate, combining RenovoCath with gemcitabine chemotherapy. RenovoRx expects to complete both patient enrollment and the second interim analysis for TIGeR-PaC by the end of H1 2025.

RenovoRx continues to grow its intellectual property (IP) portfolio, boasting 18 issued patents and 13 pending patents, as it advances commercialization and clinical trials in 2025.

The company recently published a new international patent application for its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which targets and delivers treatments directly to specific tissues using micro-vessels.

RenovoRx holds 8 issued and 6 pending U.S. patents and 10 issued and 7 pending patents outside the U.S., including its 2024 international application.

The TAMP technique aims to deliver therapies precisely to tumor sites, potentially reducing toxicities compared to systemic intravenous treatments.

RenovoRx's Phase III TIGeR-PaC clinical trial, evaluating its first product candidate using the FDA-cleared RenovoCath device, is expected to complete patient enrollment and the second interim analysis by mid-2025. The company also received its first purchase orders for the RenovoCath device.